Drug Development

Company provides update of progress

Published in Hepatitis Weekly, June 3rd, 2002

Human Genome Sciences, Inc., (HGSI) recently told financial analysts in New York that the company expects to file four investigational new drug (IND) applications in 2002, seeking clearance from the U.S. Food and Drug Administration (FDA) to begin clinical trials of its new drugs.

The company announced that it has received FDA clearance to begin clinical development of a novel anticancer drug, a human monoclonal antibody to TRAIL Receptor-1 (TRAIL-R1 mAb).

William A. Haseltine, PhD, chairman and CEO, said, "TRAIL-R1 mAb is an exciting new drug with a novel mechanism of action. It may eventually offer a promising therapeutic option for the treatment...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-06-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry